Peginterferon alfa-2a
From Wikipedia, the free encyclopedia
|
Peginterferon alfa-2a
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | L03 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | C860H1353N227O255S9 |
| Mol. mass | 19241 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
? |
| Routes | ? |
Pegylated interferon alfa-2a (40kD) (commercial name PEGASYS) is an antiviral drug discovered at the pharmaceutical company F.Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system.
This drug is approved around the world for the treatment of chronic hepatitis C (including patients with HIV co-infection, cirrhosis, 'normal' levels of ALT) and has recently been approved (in the EU, U.S., China and many other countries) for the treatment of chronic hepatitis B.
[edit] See also
[edit] External links
- Interferon and hepatitis c at pegasys.com
- PMPRB at pmprb-cepmb.gc.ca
- Chemical structure at hepalife.com
- MeSH Pegasys
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||
